Cord Blood America to close acquisition of BioCells Inc

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, has recently announced that all preliminary due diligence is now complete for the acquisition of controlling interest in BioCells, Inc.

BioCells is headquartered in Argentina, with affiliates under development in Peru, Colombia, Bolivia, Panama and Puerto Rico. The company is the second largest stem cell storage company in Argentina, and is considered to be profitable, with annual revenues of $1.2 million in 2009 according to a press release regarding the acquisition. The company also has 12 locations throughout Argentina, plus a recent expansion into Uruguay and Paraguay.

On April 19, 2010, Cord Blood America announced that a letter of intent had been signed by both companies for Cord Blood America to purchase controlling interest in BioCells.

"We are very confident that this acquisition will close by the end of August," said Matthew Schissler, Cord Blood America co-founder and CEO. "Having controlling interest in BioCells will significantly boost our bottom line by one to one and a half million dollars annually. It's a historic day when CBAI can add a profitable entity to its family of companies. It is our goal to build Cord Blood America into the world's premier stem cell storage company, with current transactions being completed in Germany, as a foundation for all of Europe, and in China."

The acquisition is expected to be closed no later than August 31, 2010.

"We also are announcing that we are exploring ways that we can reward our loyal shareholders once this transaction is complete," Mr. Schissler said.